Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Viardot, Andreas, Goebeler, Marie-Elisabeth, Hess, Georg, Neumann, Svenja, Pfreundschuh, Michael, Adrian, Nicole, Zettl, Florian, Libicher, Martin, Sayehli, Cyrus, Stieglmaier, Julia, Zhang, Alicia, Nagorsen, Dirk, Bargou, Ralf C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2016
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4797019/
https://ncbi.nlm.nih.gov/pubmed/26755709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-06-651380
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares